Spots Global Cancer Trial Database for prednisone
Every month we try and update this database with for prednisone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00005959 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | NCT00450385 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - 120 Years | University of Miami | |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT00736450 | Contiguous Stag... Noncontiguous S... Stage I Adult D... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone biopsy microarray anal... immunohistochem... gene expression... cytogenetic ana... | 19 Years - | University of Nebraska | |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | NCT02522715 | Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone | 18 Years - | OHSU Knight Cancer Institute | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | NCT06136624 | Prostate Cancer... | Opevesostat Abiraterone ace... Enzalutamide Hydrocortisone Fludrocortisone... Prednisone Dexamethasone | - | Merck Sharp & Dohme LLC | |
| Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | NCT00313781 | Prostatic Neopl... | CP-751,871 docetaxel prednisone docetaxel prednisone | 18 Years - | Pfizer | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | NCT00451178 | Lymphoma | enzastaurin rituximab cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - | Eli Lilly and Company | |
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00070447 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | NCT03719105 | NK-Cell Lymphom... NK-Cell Leukemi... Peripheral T Ce... | Methotrexate pralatraxate, Ifosfamide Dexamethasone Etoposide calaspargase pe... cyclophosphamid... Doxorubicin Prednisone Brentuximab Ved... | 1 Year - 31 Years | New York Medical College | |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | NCT00026208 | Lymphoma, Hodgk... Lymphoma Hodgkin Disease Lymphoma: Hodgk... | Vincristine Cyclophosphamid... Doxorubicin Prednisone Bleomycin Etoposide Low-dose radiot... | 18 Years - 70 Years | Stanford University | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | NCT03536039 | Lymphoma, Large... | NGR-hTNF RITUXIMAB Doxorubicin Cyclophosphamid... Vincristine Prednisone | 18 Years - 80 Years | IRCCS San Raffaele | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | NCT00004010 | Lymphoma | bleomycin sulfa... filgrastim ABVD regimen cyclophosphamid... dacarbazine doxorubicin hyd... etoposide prednisone procarbazine hy... vinblastine sul... vincristine sul... radiation thera... | - 21 Years | Children's Oncology Group | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | NCT00002785 | Leukemia | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine mesna methotrexate methylprednisol... pegaspargase prednisone therapeutic hyd... vincristine sul... allogeneic bone... low-LET cobalt-... low-LET photon ... | - 1 Year | Children's Oncology Group | |
| Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00006890 | Multiple Myelom... | prednisone thalidomide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | NCT00049569 | L1 Childhood Ac... L2 Childhood Ac... Non-T, Non-B Ch... Recurrent Child... T-cell Childhoo... | cytarabine methotrexate vincristine sul... prednisone pegaspargase doxorubicin hyd... imatinib mesyla... cyclophosphamid... etoposide filgrastim leucovorin calc... asparaginase therapeutic hyd... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| A Study in Adults With Untreated Acute Lymphoblastic Leukemia | NCT00136435 | Acute Lymphobla... | prednisone doxorubicin vincristine methotrexate asparaginase dexamethasone cranial radiati... leucovorin cytarabine hydrocortisone 6-mercaptopurin... e. coli L-aspar... | 18 Years - 50 Years | Dana-Farber Cancer Institute | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | NCT05453500 | B Acute Lymphob... | Bone Marrow Asp... Cyclophosphamid... Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine | 18 Years - | University of Washington | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | NCT02663193 | Prostate Cancer | No Intervention | 18 Years - | Janssen Scientific Affairs, LLC | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | NCT00006184 | Multiple Myelom... | Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00032019 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | - | Alliance for Clinical Trials in Oncology | |
| A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma | NCT04780464 | Advanced Soft-t... | Doxorubicin Doxorubicin Cyclophosphamid... Prednisolone Prednisone | 65 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | NCT00408005 | T Acute Lymphob... T Lymphoblastic... | Asparaginase Cyclophosphamid... Cytarabine Daunorubicin Hy... Dexamethasone Doxorubicin Hyd... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Nelarabine Pegaspargase Prednisone Radiation Thera... Thioguanine Vincristine Sul... | 1 Year - 30 Years | National Cancer Institute (NCI) | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | NCT02406092 | Non-Hodgkin Lym... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Fludarabine | 18 Years - 80 Years | Hoffmann-La Roche | |
| Taxotere Prostate Cancer New Indication Registration Trial in China | NCT00436839 | Prostatic Neopl... | Docetaxel Mitoxantrone Prednisone | - | Sanofi | |
| Immune Suppression Of Infants Treated With Steroids | NCT00433940 | Hemangioma | Prednisolone | - 6 Months | Medical College of Wisconsin | |
| Treatment for Classical Hodgkin Lymphoma in Children and Adolescents | NCT02797717 | Classical Hodgk... | Radiotherapy: Vincristine Etoposide Prednisone Doxorubicin Dacarbazine Cyclophosphamid... | 1 Month - 18 Years | Rabin Medical Center | |
| Abiraterone Acetate for Castrate Resistant Prostate Cancer | NCT01961843 | Prostate Cancer | Abiraterone Prednisone | 18 Years - | Massachusetts General Hospital | |
| Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | NCT00043979 | Sarcoma | F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo... | 5 Years - 35 Years | National Institutes of Health Clinical Center (CC) | |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | docetaxel placebo prednisone bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | NCT00054665 | B-Cell Lymphoma | PS-341 Etoposide Doxorubicin Vincristine Cyclophosphamid... Prednisone Filgrastim | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | NCT00381680 | B-cell Childhoo... L1 Childhood Ac... L2 Childhood Ac... Intermediate Ri... | vincristine sul... prednisone doxorubicin hyd... pegaspargase cytarabine methotrexate dexamethasone etoposide cyclophosphamid... leucovorin calc... filgrastim asparaginase mercaptopurine | 1 Year - 29 Years | Children's Oncology Group | |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | NCT04884035 | Lymphoma, B-Cel... | CC-220 Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone CC-99282 Polatuzumab ved... Rituximab | 18 Years - | Celgene | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | NCT03360721 | Castration-Resi... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00002756 | Leukemia | filgrastim asparaginase cyclophosphamid... cytarabine daunorubicin hy... etoposide leucovorin calc... mercaptopurine methotrexate prednisone therapeutic hyd... vincristine sul... | - 1 Year | Children's Oncology Group | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients | NCT02690922 | ph+ Acute Lymph... | Dasatinib prednisone dexamethasone methotrexate | 18 Years - | Tongji Hospital | |
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | NCT04790903 | Lymphoma, Large... | Venetoclax Polatuzumab Ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Hoffmann-La Roche | |
| Pazopanib, Docetaxel, Prednisone Prostate | NCT01385228 | Prostate Cancer | Pazopanib Docetaxel Pazopanib Prednisone Pegfilgrastim | 18 Years - | Duke University | |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | NCT03036904 | Diffuse Large B... High Grade B-Ce... | Venetoclax Rituximab Etoposide Vincristine Sul... Cyclophosphamid... Prednisone Doxorubicin Hyd... | 18 Years - 80 Years | Weill Medical College of Cornell University | |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | NCT03036904 | Diffuse Large B... High Grade B-Ce... | Venetoclax Rituximab Etoposide Vincristine Sul... Cyclophosphamid... Prednisone Doxorubicin Hyd... | 18 Years - 80 Years | Weill Medical College of Cornell University | |
| Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas | NCT03220022 | AIDS-Related Ly... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Cyclophosphamid... Doxorubicin Hyd... Etoposide Filgrastim Ibrutinib Laboratory Biom... Pegfilgrastim Pharmacological... Prednisone Rituximab Vincristine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | NCT03952572 | Peripheral T-ce... | Cyclophosphamid... pegylated lipos... Vincristine Prednisone Doxorubicin | 18 Years - 75 Years | Peking University | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | NCT03617432 | Experimental Tu... | Chidamide Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone | 18 Years - 70 Years | Peking University | |
| A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | NCT05800366 | Lymphoma Lymphoma, Large... | Glofitamab Polatuzumab Rituximab Doxorubicin Hyd... Cyclophosphamid... Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01424930 | Prostate Neopla... Prostate Cancer | Abiraterone Prednisone | 18 Years - | Janssen-Ortho Inc., Canada | |
| A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | NCT03758989 | DLBCL | Rituximab Predn... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | University of Rochester | |
| Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | NCT05605899 | High-risk Large... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Etoposide Rituximab Doxorubicin Vincristine Prednisone | 18 Years - | Gilead Sciences | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | NCT02034552 | Prostatic Neopl... | Radium-223 dich... Abiraterone ace... Prednisone Enzalutamide | 18 Years - | Bayer | |
| PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | NCT00512980 | Hodgkin Lymphom... | prednisone vinblastine doxorubicin gemcitabine | 18 Years - 60 Years | University of Cologne | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | NCT02685267 | Prostate Cancer | Docetaxel Enzalutamide Prednisone | 18 Years - | Prostate Cancer Clinical Trials Consortium | |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | NCT03821792 | Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | NCT01792687 | Prostate Cancer | ARN-509 Abiraterone ace... Prednisone | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT01718353 | Prostate Cancer... | DOCETAXEL (XRP6... CABAZITAXEL (XR... Prednisone | 18 Years - | Sanofi | |
| RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | NCT03536039 | Lymphoma, Large... | NGR-hTNF RITUXIMAB Doxorubicin Cyclophosphamid... Vincristine Prednisone | 18 Years - 80 Years | IRCCS San Raffaele | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
